Advanced Non-squamous and squamous NSCLC - Pipeline Insight, 2024

This “Advanced Non-Squamous & Squamous NSCLC - Pipeline Insight, 2024,” report provides comprehensive insights about 9+ companies and 10+ pipeline drugs in Advanced Non-Squamous & Squamous NSCLC pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Advanced Non-Squamous & Squamous NSCLC Understanding

Advanced Non-Squamous & Squamous NSCLC: Overview

Lung cancer is one of the most common types of cancer across the globe and among the leading causes of cancer-related deaths. Non-small cell lung cancer (NSCLC) accounts for approximately 85% of all lung cancers and is further classified into squamous NSCLC and non-squamous NSCLC (includes large cell histologies and adenocarcinoma). Advanced non-small cell lung cancer (NSCLC) is a severe disease with burdensome symptoms and traditionally poor outcomes. The treatment of advance disease is based on chemotherapy, with the recent addition of immunotherapy. Anti-programmed death 1 (PD-1) and programmed death ligand 1 (PD-L1) monoclonal antibodies are commonly used for advanced non-squamous and squamous non-small cell lung cancer, preferably in patients with high PD-L1 expression (tumour proportion score [TPS] =50%) and no targetable driver mutations in epidermal growth factor receptor (EGFR), MET exon 14 skipping alterations, or gene fusions in ALK, ROS1, RET, and TRK.

Advanced Non-Squamous & Squamous NSCLC - Pipeline Insight, 2024 report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Advanced Non-Squamous & Squamous NSCLC pipeline landscape is provided which includes the disease overview and Advanced Non-Squamous & Squamous NSCLC treatment guidelines. The assessment part of the report embraces, in depth Advanced Non-Squamous & Squamous NSCLC commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Advanced Non-Squamous & Squamous NSCLC collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Advanced Non-Squamous & Squamous NSCLC R&D. The therapies under development are focused on novel approaches to treat/improve Advanced Non-Squamous & Squamous NSCLC.

Advanced Non-Squamous & Squamous NSCLC Emerging Drugs Chapters

This segment of the Advanced Non-Squamous & Squamous NSCLC report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Advanced Non-Squamous & Squamous NSCLC Emerging Drugs

KN-046: Jiangsu Alphamab BiopharmaceuticalsKN-046 is a bispecific antibody targeting both programmed death-ligand 1 (PD-L1) and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4). The drug is in Phase III clinical studies for the treatment of Advanced Squamous Non-small Cell Lung Cancer.

Pyrotinib: Jiangsu HengRui MedicinePyrotinib is an irreversible dual pan-ErbB receptor tyrosine kinase inhibitor developed for the treatment of HER2-positive advanced solid tumours. The drug is in Phase III clinical studies in patients with advanced non-squamous NSCLC harboring a HER2 exon 20 mutation who failed platinum based chemotherapy.

Advanced Non-Squamous & Squamous NSCLC: Therapeutic Assessment

This segment of the report provides insights about the different Advanced Non-Squamous & Squamous NSCLC drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Advanced Non-Squamous & Squamous NSCLC

There are approx. 9+ key companies which are developing the therapies for Advanced Non-Squamous & Squamous NSCLC. The companies which have their Advanced Non-Squamous & Squamous NSCLC drug candidates in the most advanced stage, i.e. Phase III include, Jiangsu Alphamab Biopharmaceuticals.

Phases

This report covers around 10+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive

Route of Administration

Advanced Non-Squamous & Squamous NSCLC pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Parenteral
• Intravitreal
• Subretinal
• Topical

Molecule Type

Products have been categorized under various Molecule types such as

• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Advanced Non-Squamous & Squamous NSCLC: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Advanced Non-Squamous & Squamous NSCLC therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Advanced Non-Squamous & Squamous NSCLC drugs.

Advanced Non-Squamous & Squamous NSCLC Report Insights

• Advanced Non-Squamous & Squamous NSCLC Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Advanced Non-Squamous & Squamous NSCLC Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Advanced Non-Squamous & Squamous NSCLC drugs?
• How many Advanced Non-Squamous & Squamous NSCLC drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Advanced Non-Squamous & Squamous NSCLC?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Advanced Non-Squamous & Squamous NSCLC therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Advanced Non-Squamous & Squamous NSCLC and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Jiangsu Alphamab Biopharmaceuticals
• Jiangsu HengRui Medicine
• Daiichi Sankyo Company
• Genentech
• Sinocelltech
• Merck KGaA
• Mirati Therapeutics
• Ability Pharmaceuticals
• Axelar AB

Key Products

• KN-046
• Pyrotinib
• Trastuzumab deruxtecan
• Tiragolumab
• SCT-I10A
• Avelumab
• Sitravatinib
• ABTL0812
• Camrelizumab
• Picropodophyllin

This product will be delivered within 2 business days.